Trial Profile

A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adavosertib (Primary)
Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

24 Sep 2019 Status changed from active, no longer recruiting to completed.
03 Apr 2019 Results reporting safety and efficacy data from expansion cohorts presented at the 110th Annual Meeting of the American Association for Cancer Research
05 Feb 2019 Planned End Date changed from 1 Oct 2018 to 31 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com